BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
57.35
-0.87 (-1.49%)
At close: Apr 17, 2026

Revenue by Segment

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Income from sale of Products
1.08B1.15B1.02B877.52M927.80M
Income from sale of Products Growth
-6.10%12.27%16.63%-5.42%38.38%
Income from Technology
44.46M39.22M75.80M84.39M67.78M
Income from Technology Growth
13.37%-48.26%-10.17%24.50%44.17%
Equity Share Income
66.07M60.04M61.90M51.39M54.58M
Equity Share Income Growth
10.04%-3.02%20.46%-5.86%-17.59%
Total
1.19B1.25B1.16B1.01B1.05B
Total Growth
-4.71%7.50%14.59%-3.51%34.00%

Revenue by Geography

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Overseas
519.71M575.46M396.70M441.36M488.72M
Overseas Growth
-9.69%45.06%-10.12%-9.69%19.85%
China
669.79M672.82M764.48M571.93M561.43M
China Growth
-0.45%-11.99%33.67%1.87%49.35%
Total
1.19B1.25B1.16B1.01B1.05B
Total Growth
-4.71%7.50%14.59%-3.51%34.00%
Source: S&P Global Market Intelligence.